In Bottle of Lies: Ranbaxy and The Dark Side of Indian Pharma, Author Katherine Eban investigates the fall of Ranbaxy — a doom of its own making
Investors worry about poor corporate governance practices at Sun Pharma and price erosion in the US generics market
Secret Diary of Ajay Piramal — Part 2
Rising chronic illnesses and increasing health insurance coverage will spur domestic pharma industry growth
What makes Intas the most valuable privately-held pharma company in India
Vishnukant Bhutada’s big bet on oncology has catapulted Shilpa Medicare into the global generics space
Fortis Healthcare promoters are unlocking some value on their own
Sun Pharma has a robust pipeline in specialty business which will drive its profitability and free cash flow in the near future
After a dream run, Sun Pharma is grappling with growth and regulatory issues. Can the country’s biggest drug maker rediscover its mojo?
Pharma companies are giving OTC brands a makeover by splurging on advertising
Dilip Shanghvi holding on to what he has created even as his peers cash out shows his confidence in the business
India's most reticent billionaire is betting his money on the alternative energy space and here's why
Can Sun Pharma’s Dilip Shanghvi work his merger magic on Ranbaxy?
Bobby Surendranath’s secret sauce — investing in remote real estate and being patient
When it comes to technological innovation, India is still a laggard, despite increasing budgetary allocation to science
The Cipla chairman on how he and his team grew a Rs.50 lakh company to one that now does sales of over Rs.10,000 crore